This company has been acquired
NARI Stock Overview
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Inari Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$79.97 |
| 52 Week High | US$79.99 |
| 52 Week Low | US$36.73 |
| Beta | 1.03 |
| 1 Month Change | 0.53% |
| 3 Month Change | 63.20% |
| 1 Year Change | 37.62% |
| 3 Year Change | 3.51% |
| 5 Year Change | n/a |
| Change since IPO | 88.12% |
Recent News & Updates
Recent updates
Inari Medical, Inc. (NASDAQ:NARI) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Nov 07
Investors Interested In Inari Medical, Inc.'s (NASDAQ:NARI) Revenues
Sep 23Inari Medical: A Touch Of Uncertainty And Overvaluation
Jul 05At US$43.23, Is It Time To Put Inari Medical, Inc. (NASDAQ:NARI) On Your Watch List?
Jun 18Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher
May 23Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?
May 02Inari Medical: Buy On Growing TAM
Mar 27Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge
Mar 08Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)?
Dec 14A Look At The Fair Value Of Inari Medical, Inc. (NASDAQ:NARI)
Oct 23Inari Medical (NASDAQ:NARI) Is In A Strong Position To Grow Its Business
Sep 18Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?
Aug 14Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jul 25We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth
Jun 18Shareholder Returns
| NARI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.1% | 1.6% | 0.5% |
| 1Y | 37.6% | 9.7% | 11.1% |
Return vs Industry: NARI exceeded the US Medical Equipment industry which returned 12.9% over the past year.
Return vs Market: NARI exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| NARI volatility | |
|---|---|
| NARI Average Weekly Movement | 11.5% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NARI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NARI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,300 | Drew Hykes | www.inarimedical.com |
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons.
Inari Medical, Inc. Fundamentals Summary
| NARI fundamental statistics | |
|---|---|
| Market cap | US$4.69b |
| Earnings (TTM) | -US$78.58m |
| Revenue (TTM) | US$574.50m |
Is NARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NARI income statement (TTM) | |
|---|---|
| Revenue | US$574.50m |
| Cost of Revenue | US$75.74m |
| Gross Profit | US$498.76m |
| Other Expenses | US$577.34m |
| Earnings | -US$78.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.34 |
| Gross Margin | 86.82% |
| Net Profit Margin | -13.68% |
| Debt/Equity Ratio | 0% |
How did NARI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/18 04:15 |
| End of Day Share Price | 2025/02/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inari Medical, Inc. is covered by 3 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nisala Weerasuriya | Berenberg |
| Kristen Stewart | CL King & Associates, Inc. |
| null null | Equisights |